STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #290 by analyst upside · 2026-09-16
CATX
Perspective Therapeutics, Inc.
Healthcare · Market Cap $312M · P/E 0x
ANALYST PRICE TARGET
+350.0%
implied upside to consensus target
Current Price $2.73
Consensus Target $12.29
Bull Target $18.0
Bear Target $5.0
Analysts Covering 14
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
11
Hold
1
Sell
0
52-Week Low $1.96
52-Week High $6.16
YTD Return -2.2%
FUNDAMENTALS
Market Cap $312M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.33
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $0M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $1.96
52-Week High $6.16
Current Price $2.73
Bear Target $5.0
Bull Target $18.0
● Now $2.73 ● Target $12.29
TRADING DATA
Avg Volume 1.6M
YTD Return -2.2%
Analyst Count 14
Consensus Buy
Upside to Target +350.0%
Last Updated 2026-09-16

ANALYST SUMMARY

Perspective Therapeutics, Inc. (CATX) is currently trading at $2.73 with a Wall Street consensus price target of $12.29, implying potential upside of 350.0% over the next 12 months. 14 analysts currently cover CATX, with a consensus rating of Buy - 93% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $18.0, while the most cautious has a target of $5.0.

CATX operates in the Healthcare sector with a market capitalisation of $312M. The stock is down 2.2% year-to-date and is currently trading near the lower end of its 52-week range of $1.96 – $6.16.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for CATX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

BMO Capital ● Initiated
Outperform 2026-08-19 Building track record
B of A Securities - Reiterated
Neutral → Neutral 2026-08-14 Building track record
Piper Sandler - Reiterated
Overweight → Overweight 2026-08-11 14% win rate (7 calls)
Wedbush reit
Outperform → Outperform 2026-05-05 Building track record
Wedbush reit
Outperform → Outperform 2026-04-20 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-03-23 31% win rate (48 calls)
B. Riley Securities - Reiterated
Buy → Buy 2026-03-18 17% win rate (6 calls)
UBS - Reiterated
Buy → Buy 2026-03-18 33% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
43
out of 100
Coverage depth
21/30
Consensus clarity
0/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →